The trick leronlimab (pro 140) has is the ability to allow chemokine binding at the CCR5 site, chemokines are important inflammation regulators. All the other CCR5 blockers (like maraviroc) bind deep in the pocket of CCR5 and stops this critical chemokine molecule from binding.


This 3 minute video is a must see for any CYDY investor on how it works.



https://www.youtube.com/watch?v=sCMwoVYeRA0